Literature DB >> 23743932

Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung.

Hans-Ulrich Schildhaus1, Karl-Friedrich Deml, Katja Schmitz, Maren Meiboom, Elke Binot, Sven Hauke, Sabine Merkelbach-Bruse, Reinhard Büttner.   

Abstract

Reliable detection of anaplastic lymphoma kinase (ALK) rearrangements is a prerequisite for personalized treatment of lung cancer patients, as ALK rearrangements represent a predictive biomarker for the therapy with specific tyrosine kinase inhibitors. Currently, fluorescent in situ hybridization (FISH) is considered to be the standard method for assessing formalin-fixed and paraffin-embedded tissue for ALK inversions and translocations. However, FISH requires a specialized equipment, the signals fade rapidly and it is difficult to detect overall morphology and tumor heterogeneity. Chromogenic in situ hybridization (CISH) has been successfully introduced as an alternative test for the detection of several genetic aberrations. This study validates a newly developed ALK CISH assay by comparing FISH and CISH signal patterns in lung cancer samples with and without ALK rearrangements. One hundred adenocarcinomas of the lung were included in this study, among them 17 with known ALK rearrangement. FISH and CISH were carried out and evaluated according to the manufacturers' recommendations. For both assays, tumors were considered positive if ≥15% of tumor cells showed either isolated 3' signals or break-apart patterns or a combination of both. A subset of tumors was exemplarily examined by using a novel EML4 (echinoderm microtubule-associated protein-like 4) CISH probe. Red, green and fusion CISH signals were clearcut and different signal patterns were easily recognized. The percentage of aberrant tumor cells was statistically highly correlated (P<0.001) between FISH and CISH. On the basis of 86 samples that were evaluable by ALK CISH, we found a 100% sensitivity and 100% specificity of this assay. Furthermore, EML4 rearrangements could be recognized by CISH. CISH is a highly reliable, sensitive and specific method for the detection of ALK gene rearrangements in pulmonary adenocarcinomas. Our results suggest that CISH might serve as a suitable alternative to FISH, which is the current gold standard.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743932     DOI: 10.1038/modpathol.2013.95

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  [New development lines in immunology. Perspective of pathology].

Authors:  J Rüschoff; D Zielinski; E Heinmöller
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 2.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

3.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 4.  Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.

Authors:  Peter P Luk; Christina I Selinger; Wendy A Cooper; Annabelle Mahar; Carsten E Palme; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta
Journal:  Head Neck Pathol       Date:  2018-11-22

5.  Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis.

Authors:  Tobias Raphael Overbeck; Dana Alina Cron; Katja Schmitz; Achim Rittmeyer; Wolfgang Körber; Sara Hugo; Juliane Schnalke; Laura Lukat; Tabea Hugo; Marc Hinterthaner; Kirsten Reuter-Jessen; Tessa Rosenthal; Joachim Moecks; Annalen Bleckmann; Hans-Ulrich Schildhaus
Journal:  Transl Lung Cancer Res       Date:  2020-06

6.  Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.

Authors:  Benedict Yan; Chik Hong Kuick; Malcolm Lim; Kavita Venkataraman; Chandana Tennakoon; Eva Loh; Derrick Lian; May Ying Leong; Manikandan Lakshmanan; Vinay Tergaonkar; Wing-Kin Sung; Shui Yen Soh; Kenneth T E Chang
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 7.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

Review 8.  Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.

Authors:  Natalia Magdalena Chrzanowska; Janusz Kowalewski; Marzena Anna Lewandowska
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

9.  RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.

Authors:  Claudia Vollbrecht; Dido Lenze; Michael Hummel; Annika Lehmann; Markus Moebs; Nikolaj Frost; Philipp Jurmeister; Leonille Schweizer; Udo Kellner; Manfred Dietel; Maximilian von Laffert
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

10.  Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.

Authors:  Christina Alidousty; Till Baar; Luciano G Martelotto; Carina Heydt; Svenja Wagener; Jana Fassunke; Nicolai Duerbaum; Andreas H Scheel; Sandra Frank; Barbara Holz; Elke Binot; Anna Kron; Sabine Merkelbach-Bruse; Michaela A Ihle; Jürgen Wolf; Reinhard Buettner; Anne Maria Schultheis
Journal:  J Pathol       Date:  2018-07-31       Impact factor: 7.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.